Efficacy, safety, and pharmacokinetics of teclistamab in Chinese patients with relapsed/refractory multiple myeloma from the China cohort of MajesTEC‐1
Teclistamab demonstrated efficacy and safety profiles in the China cohort consistent with the pivotal cohort, supporting teclistamab as a promising treatment option for triple-class exposed relapsed/refractory multiple myeloma in China.
Authors
- Yang Song (ORCID: https://orcid.org/0000-0001-7438-6290)
- Zhongjun Xia
- Xinchao Luo
- Latisha Watkins
- Weijun Fu (ORCID: https://orcid.org/0000-0002-5908-0207)
- Juanjuan Song (ORCID: https://orcid.org/0000-0002-0634-0992)
- Aijun Liao (ORCID: https://orcid.org/0009-0003-5057-2541)
- Raluca Verona (ORCID: https://orcid.org/0000-0003-0044-4341)
- Juan Du (ORCID: https://orcid.org/0000-0003-2538-4007)
- Natalia A. Quijano Cardé (ORCID: https://orcid.org/0000-0001-9379-6658)
- Clarissa Uhlar
- Ting Niu (ORCID: https://orcid.org/0000-0003-1580-1014)
- Zhuolu Niu
- Katherine Chastain
- Lin Huang (ORCID: https://orcid.org/0000-0002-4892-7871)
- Zhen Cai (ORCID: https://orcid.org/0000-0001-6026-3804)
- Jingyun Li (ORCID: https://orcid.org/0000-0001-8013-3820)
- Yafei Wang (ORCID: https://orcid.org/0000-0003-1251-8117)
- Yue Guo (ORCID: https://orcid.org/0009-0002-2022-6982)
- Hongmei Xu (ORCID: https://orcid.org/0000-0002-7624-8016)
- Yujun Dong (ORCID: https://orcid.org/0000-0002-7935-6194)
- Aili He (ORCID: https://orcid.org/0000-0002-2610-8146)
- Longen Zhou
Institutions
- Sun Yat-sen University (CN)
- Peking University (CN)
- Sichuan University (CN)
- Tianjin Medical University Cancer Institute and Hospital (CN)
- West China Hospital of Sichuan University (CN)
- Shanghai Changzheng Hospital (CN)
- Peking University First Hospital (CN)
- Second Affiliated Hospital of Xi'an Jiaotong University (CN)
- Sun Yat-sen University Cancer Center (CN)
- Janssen (United States) (US)
- First Affiliated Hospital Zhejiang University (CN)
- China Medical University (CN)
Publication Details
- Journal
- Cancer
- Published
- 2024-12-11
- DOI
- https://doi.org/10.1002/cncr.35665
- Citations
- 6
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.73
Funders
- Janssen Research and Development